Scarica l'app Stockscreener
0.5318
3.56%
0.0183
Dopo l'orario di chiusura:
.52
-0.0118
-2.22%
Precedente Chiudi:
$0.5135
Aprire:
$0.52
Volume 24 ore:
127.90K
Relative Volume:
0.31
Capitalizzazione di mercato:
$19.57M
Reddito:
$3.04M
Utile/perdita netta:
$-33.97M
Rapporto P/E:
-0.3998
EPS:
-1.33
Flusso di cassa netto:
$-52.47M
1 W Prestazione:
+5.10%
1M Prestazione:
-4.52%
6M Prestazione:
-63.58%
1 anno Prestazione:
-86.26%
Intervallo 1D:
$0.52
$0.5375
Intervallo di 1 settimana:
$0.4928
$0.5978
Portata 52W:
$0.4619
$4.19
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Nome
Rani Therapeutics Holdings Inc
Settore
Industria
Telefono
(408) 457-3700
Indirizzo
2051 RINGWOOD AVENUE, SAN JOSE
Confronta RANI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.5318 | 19.57M | 3.04M | -33.97M | -52.47M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-06-14 | Iniziato | Maxim Group | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-07-27 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Rani Therapeutics Holdings Inc Borsa (RANI) Ultime notizie
291,381 Shares in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Purchased by Two Sigma Investments LP - Defense World
110,163 Shares in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Purchased by Two Sigma Advisers LP - Defense World
Rani Therapeutics announces annual meeting results By Investing.com - Investing.com India
Rani Therapeutics announces annual meeting results - Investing.com
Rani Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Consensus PT from Brokerages - Defense World
What is Zacks Small Cap’s Estimate for RANI Q3 Earnings? - Defense World
Q2 Earnings Estimate for RANI Issued By Zacks Small Cap - Defense World
Rani Therapeutics (NASDAQ:RANI) Stock Price Up 7% – Here’s What Happened - Defense World
Rani Therapeutics Secures $4.3M via Series D Warrant - TipRanks
Rani Therapeutics strikes deal to issue new warrants - Investing.com
Rani Therapeutics strikes deal to issue new warrants By Investing.com - Investing.com Nigeria
Rani Therapeutics Announces Research Agreement with Chugai - GlobeNewswire
Rani Therapeutics explores oral delivery of Chugai’s drugs - Investing.com Australia
RANI: 1Q:25 Financial Results - MSN
Rani Therapeutics (RANI) Partners with Chugai for Innovative Research | RANI Stock News - GuruFocus
Rani Therapeutics explores oral delivery of Chugai’s drugs By Investing.com - Investing.com India
Rani Therapeutics Enters Research Agreement with Chugai Pharmaceutical to Explore Oral Delivery Technology for Antibody Development - Nasdaq
Breakthrough: Rani's Oral Biologics Platform Matches Injectable Drugs in Chugai Partnership Study - Stock Titan
Oppenheimer Has Lowered Expectations for Rani Therapeutics (NASDAQ:RANI) Stock Price - Defense World
RANI Stock Update: Analyst Maintains Rating, Lowers Price Target | RANI Stock News - GuruFocus
Oppenheimer cuts Rani Therapeutics target to $4, keeps Outperform - Investing.com Australia
Oppenheimer cuts Rani Therapeutics target to $4, keeps Outperform By Investing.com - Investing.com Nigeria
Oppenheimer Adjusts Rani Therapeutics Price Target to $4 From $14, Maintains Outperform Rating - marketscreener.com
Oppenheimer Adjusts Rani Therapeutics (RANI) Price Target | RANI Stock News - GuruFocus
Rani Therapeutics Highlights Promising Preclinical Data - TipRanks
Rani Therapeutics Q1 2025 Earnings: EPS Misses at -$0.22, Revenue Surpasses Estimates at $0.2 Million - GuruFocus
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewswire
Rani Therapeutics Q1 Net Income USD -12.738 Million - marketscreener.com
Rani Therapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Rani Therapeutics Achieves Major Milestone: Oral Obesity Drug Shows Equal Success to Injections in Latest Data - Stock Titan
Ratio Analysis: Unpacking Rani Therapeutics Holdings Inc (RANI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Rani Therapeutics faces Nasdaq delisting over market value By Investing.com - Investing.com India
Rani Therapeutics faces Nasdaq delisting over market value - Investing.com
Rani Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - ADVFN
Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Monday - Defense World
Rani Therapeutics Board Restructures After DeBuono’s Retirement - TipRanks
Ratio Examination: Rani Therapeutics Holdings Inc (RANI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Daily Progress: XPLR Infrastructure LP (XIFR) Drop -1.51, Closing at 8.46 - DWinneX
Market Recap: PowerFleet Inc (AIOT)’s Negative Momentum, Closing at 5.12 - DWinneX
Market Highlights: Clear Channel Outdoor Holdings Inc (CCO) Ends on a Low Note at 1.02 - DWinneX
Post-Trade Analysis: Baytex Energy Corp (BTE) Climbs 0.61, Closing at 1.65 - DWinneX
Rani Therapeutics Holdings Inc Azioni (RANI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rani Therapeutics Holdings Inc Azioni (RANI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Imran Talat | Chief Executive Officer |
Dec 09 '24 |
Buy |
1.94 |
10,296 |
19,974 |
494,751 |
| South Cone Investments Limited | 10% Owner |
Oct 15 '24 |
Sale |
2.65 |
3,829,360 |
10,141,674 |
8,302,194 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):